Two men laughing in a car. No hands on the wheel. No stress. No traffic rage.
No $6 gas burning a hole in their wallet. The car is doing everything. You've
been told this future is "10 years away" your whole life.




Сⅼіϲk hеrе. <[link removed]>
<[link removed]>





Two men laughing in a car.

No hands on the wheel.

<[link removed]>
No stress. No traffic rage. No $6 gas burning a hole in their wallet.

The car is doing everything.

You've been told this future is "10 years away" your whole life.

It's not.

It's in this photo.

And the company that made it possible is still completely unknown to regular
investors.

See the name before that changes
<[link removed]>

If you would like to stop receiving these offers, please click here
<[link removed]>
to unsubscribe.




STRATEGY DESK




Novo Nordisk Beats Estimates and Raises Guidance, but Stock Falls as Wegovy
Growth Disappoints Investors




Novo Nordisk reported second-quarter adjusted operating profit of 33.4 billion
Danish kroner — beating the analyst consensus of 28.74 billion kroner by a
significant margin — and raised its full-year outlook, now projecting adjusted
sales and adjusted operating profit to come in between zero and minus 6% at
constant exchange rates, an improvement from the previous guidance of minus 4%
to minus 12%. The Wegovy pill — the first oral GLP-1 weight loss medication
launched in the U.S. earlier in the year — surpassed 5 million total
prescriptions since launch, with weekly prescriptions exceeding 265,000 in the
most recent tracked week, making it what the company describes as the
"strongest-ever GLP-1 volume launch in the U.S." Despite beating profit
estimates and raising guidance, U.S.-traded shares of Novo Nordisk fell
approximately 6% — a classic sell-the-news reaction by investors who had
expected even stronger results.


The gap between what the numbers say and how investors responded reflects a
company navigating simultaneous pressures from multiple directions. Novo
Nordisk is fighting to reclaim ground it has lost to Eli Lilly in the U.S.
obesity and diabetes drug market, where Lilly now holds a 60.1% share compared
to Novo's 39.4%. Lilly's injectable Zepbound has outperformed Novo's injectable
Wegovy in the U.S. market, and the competitive dynamic between the two
companies' oral weight loss pills — Lilly's Foundayo versus Novo's Wegovy pill
— represents the next major battleground. Foundayo, approved in April, is
already posting strong early sales numbers; Novo's pill slightly missed the
3.27 billion kroner analyst estimate for the quarter, coming in at 3.22 billion
kroner — a small miss that nonetheless sent a signal.






KEY TAKEAWAYS

* Novo Nordisk beat Q2 profit estimates significantly (33.4 billion DKK vs.
28.74 billion expected) and raised full-year guidance to flat-to-minus-6% from
a prior minus-4-to-minus-12%, but shares fell 6% as the Wegovy pill slightly
missed analyst expectations at 3.22 billion DKK versus 3.27 billion.
* The Wegovy pill surpassed 5 million total U.S. prescriptions since launch
— the strongest-ever GLP-1 volume launch — but Novo's 39.4% U.S.
obesity-diabetes market share against Lilly's 60.1% reflects the competitive
ground the Danish company must recover.
* Lilly's Foundayo (the oral orforglipron pill) and its upcoming retatrutide
— which achieved 28.3% average weight loss in phase 3 trials — represent the
competitive threats that will define the next chapter of the obesity drug war,
with the global market on track to exceed $100 billion annually by the early
2030s.



The broader commercial environment for GLP-1 drugs has simultaneously become
more favorable and more complex in 2026. Medicare now covers GLP-1 weight loss
medications for eligible patients under the Biden-era GLP-1 Bridge program — a
potentially enormous market expansion that could reach 20 million patients. But
Novo Nordisk and Eli Lilly both made significant price concessions to secure
Medicare coverage, accepting lower reimbursement rates in exchange for expanded
access. The European Medicines Agency separately approved Novo's Wegovy pill
and its higher-dose Wegovy 7.2 mg pen in the most recent quarter, providing new
international growth opportunities as U.S. market dynamics become increasingly
competitive.



Novo's CEO Mike Doustdar described the Wegovy pill as a "key growth driver"
and pointed to "encouraging early uptake in markets outside the US" as a sign
that the company's international expansion is gaining momentum. The company
also faces a longer-term competitive threat from retatrutide — Eli Lilly's
next-generation "triple-G agonist" that showed 28.3% average weight loss in
phase 3 trials, more effective than any existing obesity medication and on a
potential FDA approval path for next year. The obesity drug market is expected
to exceed $100 billion in annual revenue by the early 2030s, making the
competitive dynamics between Novo and Lilly one of the highest-stakes
pharmaceutical rivalries in modern history.




SOURCE:




* "Novo Nordisk Q2 2026 earnings beat, raises full-year outlook" — Quartz
* "Novo Nordisk releases earnings and guidance" — CNBC
* "Novo Nordisk's Q2 profit beats forecasts, raises outlook" — BNN Bloomberg
* "Novo Nordisk reports adjusted operating profit for Q2 2026 and raises
full-year outlook" — Yahoo Finance

 


<[link removed]>



[email protected] is on <[link removed]>
<[link removed]>Tradivore.com <[link removed]> list because you
opted in before the crowd caught on.

If we go quiet — look in promotions, updates, or wherever your inbox files
things it hasn't figured out yet.

Unsubscribe
<[link removed]>
. We'll part ways cleanly.

If something's off, you can reach us here <mailto:[email protected]>

254 Chapman Rd Ste 208 Newark, Delaware 19702.




UNSUBSCRIBE
<[link removed]>
|PRIVACY POLICY <[link removed]>




© 2026 Alpha One Marketers LLC. All rights reserved.